国产中文无码av每日更新在线观看, 亚洲天堂中文字幕一区二区三区免费, 国产口爆吞精在线观视频-黄色国产, 92福利-国内精品久久久久久99,亚洲成AV人A片不卡无码,浪潮AV无码专区,老熟女败火白浆,中文字幕日产av,色情日本免费看大片

400-885-9898
更新于 7月24日
智聯(lián)APPAPP
舉報(bào)

Talent Acquisition Manager(J17384)

1.5-3萬(wàn)·16薪
  • 上海徐匯區(qū)
  • 5-10年
  • 本科
  • 全職
  • 招1人

職位描述

社會(huì)招聘校園招聘
崗位職責(zé):
1、Responsible for mass recruitment, overseas recruitment, campus recruitment and other full life cycle hiring activities.
2、Evaluate and manage various channels, both for social and campus recruiting, such as WeChat, LinkedIn and relevant social medial.
3、Continuously attracting candidates by promoting the organization as an employer of choice in the marketplace, partnering with internal and external stakeholders to drive both short- and long-term employer branding initiatives.
4、Own the full recruiting cycle from setting recruitment intake meetings to job offers for critical roles in China.
5、Oversee the market intelligence to provide analysis of the competition and report findings, recommendations & actions to Sr. management team.
6、Provide local leadership and line management as required.
任職要求:
1、Bachelor’s degree with major in Human Resource or related.
2、8 years’ recruiting experiences in pharmaceutical or medical device industry.
3、In-house HR and/or headhunter experience in domestic and overseas R&D, commercial functions is highly preferred.
4、Able to conduct talent mapping and provide talent intelligence through direct souring.
5、Able to work under pressure, must be a team player, good at time management.
6、With the ability to handle multiple tasks simultaneously, while accessing and procuring accurate information in a fast-paced environment.
6、Good communication skills and quick leaning ability.
7、Proficient in both spoken and written English.

工作地點(diǎn)

上海徐匯區(qū)華鑫慧享城B區(qū)8棟11樓

職位發(fā)布者

鄒女士/HR

昨日活躍
立即溝通
公司Logo上海復(fù)宏漢霖生物技術(shù)股份有限公司
復(fù)宏漢霖（2696.HK）是一家國(guó)際化的創(chuàng)新生物制藥公司，致力于為全球患者提供可負(fù)擔(dān)的高品質(zhì)生物藥，產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領(lǐng)域，已在中國(guó)上市5款產(chǎn)品，在國(guó)際上市1款產(chǎn)品，18項(xiàng)適應(yīng)癥獲批，3個(gè)上市申請(qǐng)分別獲中國(guó)藥監(jiān)局、美國(guó)FDA和歐盟EMA受理。自2010年成立以來(lái)，復(fù)宏漢霖已建成一體化生物制藥平臺(tái)，高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運(yùn)營(yíng)全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心，按照國(guó)際藥品生產(chǎn)質(zhì)量管理規(guī)范（GMP）標(biāo)準(zhǔn)進(jìn)行生產(chǎn)和質(zhì)量管控，不斷夯實(shí)一體化綜合生產(chǎn)平臺(tái)，其中，上海徐匯基地已獲得中國(guó)和歐盟GMP認(rèn)證，松江基地（一）也已獲得中國(guó)GMP認(rèn)證。復(fù)宏漢霖前瞻性布局了一個(gè)多元化、高質(zhì)量的產(chǎn)品管線，涵蓋20多種創(chuàng)新單克隆抗體，并全面推進(jìn)基于自有抗PD-1單抗H藥漢斯?fàn)?的腫瘤免疫聯(lián)合療法。繼國(guó)內(nèi)首個(gè)生物類似藥漢利康?（利妥昔單抗）、中國(guó)首個(gè)自主研發(fā)的中歐雙批單抗藥物漢曲優(yōu)?（曲妥珠單抗，歐洲商品名：Zercepac?，澳大利亞商品名：Tuzucip?和Trastucip?）、漢達(dá)遠(yuǎn)?（阿達(dá)木單抗）和漢貝泰?（貝伐珠單抗）相繼獲批上市，創(chuàng)新產(chǎn)品漢斯?fàn)?（斯魯利單抗）已獲批用于治療微衛(wèi)星高度不穩(wěn)定（MSI-H）實(shí)體瘤、鱗狀非小細(xì)胞肺癌和廣泛期小細(xì)胞肺癌，成為全球首個(gè)獲批一線治療小細(xì)胞肺癌的抗PD-1單抗，其食管鱗狀細(xì)胞癌適應(yīng)癥的上市注冊(cè)申請(qǐng)也正在審評(píng)中。公司亦同步就16個(gè)產(chǎn)品在全球范圍內(nèi)開展30多項(xiàng)臨床試驗(yàn)。
公司主頁(yè)